In Vitro Activity and In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris
Preprint
- 8 May 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Objectives: The aim of our study was to investigate the in vitro activity and in vivo effica-cy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris iso-lates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutro-penic mice were infected intravenously (107 CFU/mouse). Treatment was initiated 24 hours post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06-0.25, ≤0.03-0.12, 0.12-0.5 and ≤0.03-0.12 mg/L, respectively. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens im-proved the survival in mice infected with isolates MRL40 and IFRC4050 (P-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TML617 (P=0.0049). All four echinocandins induced more than 3 logs mean CFU/gram decreases in the kidneys and hearts of mice infected with the three isolates compared to control mice, some of which were not statistically significant. Fungal growth, regardless of the isolate tested, was poorly inhibited by echinocandins in the brain. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin treated mice only blastoconidia were found. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphal production was common in controls, but not in echinocandin treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Xenosiderophore transporter gene expression and clade-specific filamentation in Candida auris killifish (Aphanius dispar) infectionCommunications Biology, 2025
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine ModelMycopathologia, 2025
- Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMThe Lancet Infectious Diseases, 2025
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trialThe Lancet, 2022
- Confirmation of fifth Candida auris clade by whole genome sequencingEmerging Microbes & Infections, 2022
- A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in IranMycopathologia, 2021
- Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine modelEmerging Microbes & Infections, 2020
- Filamentation in Candida auris , an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switchEmerging Microbes & Infections, 2018
- Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological AnalysesClinical Infectious Diseases, 2016
- Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient ManagementDrugs, 2014